Why It Matters

Heartburn that never fully goes away is one of the most common complaints in gastroenterology. A newer kind of acid blocker just put its detailed Phase 3 numbers on the table.

Braintree Laboratories, part of privately held Sebela Pharmaceuticals, said on October 11 that full results from its TRIUMpH-NERD trial of tegoprazan are being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting. Both doses beat placebo on the trial’s main heartburn goal. The FDA is already reviewing the drug, and Sebela says it anticipates a U.S. decision in January 2027.

Two wrinkles for investors. Sebela doesn’t trade on any exchange. And tegoprazan would enter a U.S. market where a drug from the same class already holds this exact approval.

What Tegoprazan Is

Tegoprazan is a potassium-competitive acid blocker, or P-CAB. Like familiar proton pump inhibitors (PPIs) such as omeprazole and lansoprazole, it cuts stomach acid by shutting down the gastric proton pump. But P-CABs block the pump reversibly by competing with potassium, and they don’t need acid to activate them, which is part of why they tend to work faster.

The target is non-erosive reflux disease, or NERD. That’s GERD (gastroesophageal reflux disease) where patients have the symptoms, mainly heartburn and regurgitation, but no visible damage to the esophagus on a scope.

Tegoprazan isn’t new everywhere. It’s sold as K-CAB in South Korea and, per the release, holds marketing authorization in 24 countries. The U.S. isn’t one of them yet.

The Heartburn Numbers

TRIUMpH-NERD (NCT05587322) randomized 783 U.S. adults with symptomatic NERD to tegoprazan 50 mg, tegoprazan 100 mg, or placebo once daily for four weeks. A 20-week extension followed.

The primary endpoint was the share of 24-hour heartburn-free days through Week 4. Placebo patients averaged 17.3%. The 50 mg group hit 26.2% (p=0.0006) and the 100 mg group 30.1% (p<0.0001). Placebo patients got about one heartburn-free day in six. On the higher dose, it was closer to one in three.

The key secondary endpoint, days without nighttime heartburn, came in at 27.0% on placebo versus 36.1% and 39.9% on the two doses (p=0.0017 and p<0.0001). Sebela says differences showed up from Day 1.

In the 20-week extension, heartburn-free days averaged 48% and 50%. That phase was open-label, with no placebo group, so those figures carry less weight.

The “First and Only” Claim

Sebela’s headline pitch is that tegoprazan is the first and only P-CAB reported to improve both heartburn and regurgitation in a prospective U.S. Phase 3 trial. That needs context.

Regurgitation was a prespecified exploratory endpoint, not a primary or key secondary one. The release gives relative gains for days free of both symptoms (60% and 76% over placebo) but no absolute regurgitation rates. And the NDA, as the release describes it, seeks approval for heartburn associated with NERD, not regurgitation.

The claim is also narrowly drawn. In May 2026, Phathom Pharmaceuticals (Nasdaq: PHAT) presented an exploratory analysis at Digestive Disease Week showing its P-CAB, vonoprazan, improved regurgitation scores versus placebo in its own Phase 3 NERD trial, using a different questionnaire. Sebela’s wording may hold on its exact terms. It doesn’t make tegoprazan the only P-CAB with regurgitation data.

A Rival Is Already Approved

Vonoprazan, sold as Voquezna, won FDA approval in July 2024 for heartburn associated with non-erosive GERD, based on the PHALCON-NERD-301 trial. It was the first P-CAB approved in the U.S. If tegoprazan gets the nod, it would be second in class here.

Lining up the two trials is tempting. It doesn’t settle much. Phathom reported a mean of about 45% heartburn-free days on vonoprazan versus 28% on placebo through Week 4, which looks higher on paper. Sebela argues its patients were sicker at the start: only 6.2% had a heartburn-free day at baseline, versus 12.9% to 22.6% in earlier PPI and P-CAB NERD studies, according to the release. But these were separate trials in different populations, never run head-to-head, so neither result proves one drug works better.

The Erosive Esophagitis Analysis

A second presentation, given an ACG Presidential Award, revisited the companion TRIUMpH-EE trial (NCT05587309). That study compared tegoprazan with lansoprazole in erosive esophagitis (EE), the form of GERD with visible esophageal damage.

Researchers reclassified patients using Lyon Consensus 2.0 criteria. In those with “conclusive” GERD (LA Grades B through D), tegoprazan healed more patients than lansoprazole at Week 2 (75.4% vs. 60.7%) and by Week 8 (83.4% vs. 72.7%). No significant difference showed up in milder, “inconclusive” Grade A cases.

This is a post hoc analysis, meaning the subgroups were defined after the trial ended. Useful for generating hypotheses. Not the same weight as a prespecified result.

Safety

Across the TRIUMpH program, individual treatment-emergent side effects occurred at roughly 3% and serious events at roughly 2%, with similar rates for tegoprazan and its comparators, according to the release. Mean serum gastrin, a hormone that rises with long-term acid suppression, stayed in the normal range. The release doesn’t break out safety data for the NERD trial alone.

Who Actually Owns It

The release lists no ticker for anyone. Sebela licensed U.S. and Canadian rights to tegoprazan from HK inno.N Corporation (KOSDAQ: 195940), the South Korean company that developed and markets K-CAB. Further upstream, Japan’s RaQualia Pharma (Tokyo Stock Exchange: 4579) originally created tegoprazan and licensed it to HK inno.N. Sebela itself is private equity-backed. Financial terms of the U.S. license were not disclosed.

What Wasn’t Disclosed

Quite a bit. There are no absolute regurgitation rates, no NERD-specific safety table, and no confirmed FDA action date, only an “anticipated” January 2027 approval. The release also doesn’t say whether the FDA has flagged any review issues. Its own forward-looking statements list Sebela’s ability to continue as a going concern and its need for additional financing among the risks, without further detail.

An anticipated approval isn’t an approval. Until the FDA acts, tegoprazan remains investigational in the U.S. This article covers clinical trial data and is not medical or investment advice.

Sources

• Sebela Pharmaceuticals: Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting, PRNewswire, October 11, 2026. Primary source release.
• Sebela Pharmaceuticals: Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada, cited for the HK inno.N licensing relationship, which the ACG release did not describe.
• HK inno.N: K-CAB U.S. Phase 3 Results at DDW 2026, cited for the January 2026 NDA submission and HK inno.N’s role as developer.
• Investing.com: HK Inno.N Corp (195940) stock profile, cited for HK inno.N’s KOSDAQ listing and ticker.
• RaQualia Pharma: Tokyo Stock Exchange disclosure on tegoprazan (Japanese), cited for RaQualia’s origination of tegoprazan and its license to HK inno.N.
• PitchBook: Sebela Pharmaceuticals company profile, cited for Sebela’s private ownership status.
• Phathom Pharmaceuticals: FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults, cited for competitive-landscape context on the already-approved rival P-CAB.
• HCPLive: Vonoprazan Receives FDA Approval for Heartburn Associated with Non-Erosive GERD, cited for the July 2024 approval date and PHALCON-NERD-301 basis.
• PharmaShots: Phathom Pharmaceuticals’ Voquezna Receives the US FDA’s Approval for Non-Erosive GERD, cited for PHALCON-NERD-301 heartburn-free day figures used in the cross-trial context.
• Phathom Pharmaceuticals: Vonoprazan Research at Digestive Disease Week 2026, cited for Phathom’s exploratory heartburn and regurgitation analysis, relevant to the release’s “first and only” claim.

Editorial Disclosure

This article reports on clinical trial data presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting regarding tegoprazan, as announced in a press release issued by Sebela Pharmaceuticals on October 11, 2026. Securities and corporate structures discussed: Sebela Pharmaceuticals (privately held, not publicly traded; developing tegoprazan through its Braintree Laboratories, Inc. unit), HK inno.N Corporation (KOSDAQ: 195940), RaQualia Pharma Inc. (Tokyo Stock Exchange: 4579), and Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT). Licensing, ownership, ticker, and competitor information was drawn from the independent sources cited above, since the original release did not address it. BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Sebela Pharmaceuticals, Braintree Laboratories, HK inno.N, RaQualia Pharma, Phathom Pharmaceuticals, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Statements regarding the anticipated January 2027 FDA decision, eventual approval prospects, the scope of any approved label, commercial launch plans, and potential competition are forward-looking statements. They involve substantial risks, regulatory uncertainties, and scientific variables; actual clinical outcomes, development timelines, and commercial approvals may differ materially. Biotechnology and pharmaceutical investments carry a high degree of financial risk. Drug development is subject to clinical failure, regulatory rejection, and market competition, which can result in the total loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full Terms & Disclaimers Page